GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,300 ($18.23) price target by stock analysts at Credit Suisse Group in a research report issued on Thursday. The firm currently has a “neutral” rating on the stock. Credit Suisse Group’s price target indicates a potential upside of 0.70% from the company’s current price.
Several other equities research analysts also recently commented on GSK. UBS Group set a GBX 1,600 ($22.43) target price on GlaxoSmithKline and gave the company a “neutral” rating in a report on Monday, October 23rd. Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($25.24) target price on shares of GlaxoSmithKline in a report on Monday, October 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,570 ($22.01) target price on shares of GlaxoSmithKline in a report on Monday, October 23rd. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a report on Monday, October 23rd. Finally, Goldman Sachs Group reiterated a “buy” rating and set a GBX 1,900 ($26.64) target price on shares of GlaxoSmithKline in a report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of GBX 1,541.36 ($21.61).
GlaxoSmithKline (LON:GSK) traded down GBX 12.80 ($0.18) during midday trading on Thursday, hitting GBX 1,291 ($18.10). The stock had a trading volume of 11,680,000 shares, compared to its average volume of 9,480,000. The firm has a market cap of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.32) and a fifty-two week high of GBX 1,724.50 ($24.18).
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.